Authors

Discussion

As for now, the majority of molecular biologists do not have ready access to suitable drug screening platforms and compound collections, which are generally expensive to purchase, operate and maintain. This represents a major limitation in the field to advance innovative drug discovery projects in academia. With the aim to address this need, researchers from 30 institutions have joined forces to lunch EU-OPENSCREEN, which offers international scientists access to a wide range of state-of-the-art screening platforms, compound libraries and expertise. Biologist with a robust and suitable assay can access EU-OPENSCREEN’s screening platforms on a collaborative basis and screen the rationally selected compound collection. EU-OPENSCREEN collaborates with the structural biology community to expand its capacity in fragment-based drug discovery.